BACKGROUNDLicense Option Agreement • May 14th, 1998 • Allergan Specialty Therapeutics Inc • Pharmaceutical preparations • California
Material Transfer and License Option Agreement between Helix BioPharma Corporation and Schering CorporationLicense Option Agreement • February 5th, 2009 • Helix BioPharma Corp • Pharmaceutical preparations • New York
INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS IDENTIFIED BY THREE ASTERISKS, AS FOLLOWS “* * *”, AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION FIRST AMENDMENT TO THE LICENSE AND EXCLUSIVE LICENSE OPTION AGREEMENTLicense Option Agreement • March 30th, 2015 • MultiVir Inc. • Pharmaceutical preparations
This Amendment (“Amendment”) to the Exclusive License and License Option Agreement, (hereinafter, the “Agreement”), executed this 15th day of May 2012, is made and entered into by and between SAINT LOUIS UNIVERSITY, a Missouri nonprofit corporation (“University”) and VIRRX, INC, a Delaware corporation (“Licensee”). The effective date of this Amendment shall be May 15th, 2012.
ContractLicense Option Agreement • November 3rd, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission.
LICENSE OPTION AGREEMENTLicense Option Agreement • December 7th, 2020
THIS LICENSE OPTION AGREEMENT (this “Agreement”), dated as of this ___ day of ____________, 20__ (the “Effective Date”), by and between Hiroshima University, a national university corporation duly organized under the laws of Japan, having a principal address at 1-3-2 Kagamiyama, Higashi-Hiroshima City, Hiroshima Pref., 739-8511, Japan (“University”), and [XYZ Corporation], a corporation duly organized under the laws of ______, having a principal place of business at ___________________, (“XYZ”).
AMENDMENT NO. 7 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • March 15th, 2007 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
THIS AMENDMENT NO. 7 TO THE LICENSE & OPTION AGREEMENT (“Amendment No. 7”) is made and entered into this 27th day of December, 2006 (the “Amendment No. 7 Effective Date”) by and between Oscient Pharmaceuticals Corporation (“OSCIENT”), a Massachusetts corporation, having a principal place of business at 1000 Winter Street, Suite 2200, Waltham, Massachusetts 02451, and LG Life Sciences, LTD (“LGLS”), a corporation organized under the laws of the Republic of Korea, having a principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea. LGLS and OSCIENT may be referred to herein individually as a “Party” and collectively as the “Parties”.
AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • December 3rd, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENT (“the Amendment”) is made and entered into this 16th day of October, 2003 (the “Amendment Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea, having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS may be referred to herein individually as a “Party” and collectively as the “Parties.”
License Option AgreementLicense Option Agreement • May 16th, 2016 • Immune Pharmaceuticals Inc • Pharmaceutical preparations
This Agreement made this day of May 15, 2016 by and between Immune Pharmaceuticals Inc. (“Immune”) with a principal place of business at 430 East 29th Street, Suite 940, New York, NY 10016 and Novel Pain Therapeutics LLC (“NPT”), a newly formed limited liability company with an office at 52 East End Avenue #12A New York, NY 10028
LICENSE OPTION AGREEMENTLicense Option Agreement • March 14th, 2012 • Biotime Inc • Biological products, (no disgnostic substances) • California
This License Option Agreement (“Agreement”) is made and entered into as of December 15, 2011 (the “Effective Date”), by and between BioTime, Inc., a California corporation (“BioTime”), with offices located at 1301 Harbor Bay Parkway, Suite 100, Alameda, California 94502, and USCN, a Chinese company with offices located at 108 Zhuanyang Avenue Economic & Technological Development Zone, Wuhan 430056 (“USCN”). USCN and BioTime are sometimes hereinafter referred to as the “Parties”.
AMENDMENT NO. 1 TO LICENSE OPTION AGREEMENTLicense Option Agreement • July 19th, 2016 • Immune Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Amendment No. 1 to the License Option Agreement (the "Agreement") made and entered into as of the 18th day of July 2016, between Immune Pharmaceuticals Inc., a Delaware corporation (“Immune”) and Novel Pain Therapeutics, LLC., a New York limited liability company (“NPT”), both referred to hereinafter referred to as the "Parties."
ContractLicense Option Agreement • March 5th, 2010 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission.
EXHIBIT 10.10 *CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT* EXCLUSIVE PATENT AND KNOW HOW LICENSE OPTION AGREEMENT This Exclusive Patent and Know...License Option Agreement • January 5th, 2006 • Safetek International Inc • Miscellaneous plastics products
AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • May 11th, 2004 • Oscient Pharmaceuticals Corp • In vitro & in vivo diagnostic substances • California
THIS AMENDMENT NO. 3 TO LICENSE & OPTION AGREEMENT (“the Amendment”) is made and entered into this 16th day of October, 2003 (the “Amendment Effective Date”) by and between GENESOFT PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 7300 Shoreline Court, South San Francisco, CA, USA 94080 (“GS”) and LG LIFE SCIENCES, LTD., a corporation organized under the laws of the Republic of Korea, having its principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea (“LGLS”). LGLS and GS may be referred to herein individually as a “Party” and collectively as the “Parties.”
RESEARCH AND COMMERCIAL LICENSE OPTION AGREEMENTLicense Option Agreement • March 16th, 2006 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances) • Delaware
This Research and Commercial License Option Agreement (the “Agreement”) is made and entered into as of October 1, 2005 (the “Effective Date”) by and between Sangamo BioSciences, Inc., a Delaware corporation having its principal place of business at Point Richmond Tech Center, 501 Canal Boulevard, Suite A100, Richmond, California 94804 (“Sangamo”), and Dow AgroSciences LLC, a Delaware limited liability company having its principal place of business at 9330 Zionsville Road, Indianapolis, Indiana 46268 (“DAS”). Sangamo and DAS are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ContractLicense Option Agreement • October 27th, 2016 • Sangamo Biosciences Inc • Biological products, (no disgnostic substances)
NOTE: Portions of this Exhibit are the subject of a Confidential Treatment Request by the Registrant to the Securities and Exchange Commission (the “Commission”). Such portions have been redacted and are marked with a “[***]” in the place of the redacted language. The redacted information has been filed separately with the Commission.
AMENDMENT No. 5 TO LICENSE & OPTION AGREEMENTLicense & Option Agreement • May 10th, 2006 • Oscient Pharmaceuticals Corp • Pharmaceutical preparations
THIS AMENDMENT No. 5 TO THE LICENSE & OPTION AGREEMENT (“Amendment No. 5”) is made and entered into this February 3, 2006 (the “Amendment No. 5 Effective Date”) by and between Oscient Pharmaceuticals Corporation (“OSCIENT”), a Massachusetts corporation, having a principal place of business at 1000 Winter Street, Suite 2200, Waltham, MA 02451, and LG Life Sciences, LTD (“LGLS”), a corporation organized under the laws of the Republic of Korea, having a principal place of business at LG Twin Tower, 20 yoido-dong, Youngdungpo-gu, Seoul, 150-721, Republic of Korea. LGLS and OSCIENT may be referred to herein individually as a “Party” and collectively as the “Parties”.
